Trial Profile
A Phase II Single-arm Trial of BIBW 2992 in Demographically and Genotypically Selected NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 08 Feb 2012 Actual patient number 41 added as reported by ClinicalTrials.gov.
- 08 Feb 2012 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
- 08 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.